Serum DNA binding activity in healthy subjects and in rheumatic disease
β Scribed by Peter Hasselbacher; E. Carwile LeRoy
- Publisher
- John Wiley and Sons
- Year
- 1974
- Tongue
- English
- Weight
- 466 KB
- Volume
- 17
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Modifications of the Farr ammonium sulfate precipitation assay for DNA antibodies have increased sensitivity and led to the detection of DNA binding in the sera of healthy subjects and subjects with rheumatic disease other than systemic lupus erythematosus (SLE). The presence of binding in immunochemically pure IgG and the pattern of inhibition by native and denatured DNA support the thesis that DNA binding of normal, nonβSLE, and SLE sera is antibody and similar in kind although not in degree. The presence of antibodies to DNA in normal and nonβSLE sera may limit the qualitative role of these antibodies in SLE and render DNA antibodies similar to antiglobulin and other antinuclear antibodies in rheumatic disease.
π SIMILAR VOLUMES
Free radicals are considered to be important factors involved in many physiopathological processes. Several methods have been proposed for studying the mechanisms of antioxidant protection against free radical-induced injury, including the measurement of the total antioxidant capacity (TAC) in body
Quantitation of the PET benzodiazepine receptor antagonist, [ 11 C]Iomazenil, using low specific activity radioligand was recently described. The purpose of this study was to quantitate benzodiazepine receptor binding in human subjects using PET and high specific activity [ 11 C]Iomazenil. Six healt
Chronic disabling disease compromises quality of life. Among the factors most widely recognized as responsible for such effects among people with rheumatic conditions are pain, disability, and a host of ensuing psychological changes (e.g., helplessness, hopelessness, and depression). Disease and dis